Literature DB >> 16055931

Pathologic and immunohistochemical findings in hypothalamic and mesencephalic regions in the pah(enu2) mouse model for phenylketonuria.

Jennifer E Embury1, Roger R Reep, Philip J Laipis.   

Abstract

The Pah(enu2) mouse, created through ethylnitrosurea mutagenesis, is a model for phenylketonuria. These mice have elevated serum phenylalanine levels, hypopigmentation, and behavior and movement abnormalities, and female mice exhibit a maternal phenylketonuria syndrome. We evaluated the brains of adult and juvenile Pah(enu2) mice for consistent, demonstrable lesions to elucidate various neuropathologic processes and to assess the efficacy of various treatment modalities such as AAV-mediated gene therapy. One aspect of the disease may involve the effect of hyperphenylalanemia on catecholamine function. High levels of phenylalanine inhibit enzymes that are important in the conversion of tyrosine and tryptophan to their respective neurotransmitter derivatives, including dopamine. Therefore, assessment of dopaminergic regions was of interest in this study. Histologic evaluation of juvenile and adult brains revealed an increased cellular density as early as 4 wk of age in the middle to posterior hypothalamus and substantia nigra. The infiltrating cells showed immunoreactivity for CD11b and had morphologic characteristics of macrophages. There was marked expression of inducible nitric oxide synthase in these dopaminergic regions that co-localized to CD11b-positive cells. The CD11b-positive cells and increased inducible nitric oxide synthase expression in these regions may function in a neuroregulatory manner to compensate for alterations in dopamine metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16055931      PMCID: PMC1876945          DOI: 10.1203/01.PDR.0000170000.78670.44

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  20 in total

1.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease.

Authors:  G T Liberatore; V Jackson-Lewis; S Vukosavic; A S Mandir; M Vila; W G McAuliffe; V L Dawson; T M Dawson; S Przedborski
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms.

Authors:  Anthony R West; Matthew P Galloway; Anthony A Grace
Journal:  Synapse       Date:  2002-06-15       Impact factor: 2.562

3.  Experimental hyperphenylalaninemia provokes oxidative stress in rat brain.

Authors:  Martine E Kienzle Hagen; Carolina D Pederzolli; Angela M Sgaravatti; Raquel Bridi; Moacir Wajner; Clóvis M D Wannmacher; Angela T S Wyse; Carlos S Dutra-Filho
Journal:  Biochim Biophys Acta       Date:  2002-04-24

4.  Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation.

Authors:  L Trabace; K M Kendrick
Journal:  J Neurochem       Date:  2000-10       Impact factor: 5.372

5.  A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients.

Authors:  S Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

6.  Oxidative stress in a phenylketonuria animal model.

Authors:  Nuran Ercal; Nukhet Aykin-Burns; Hande Gurer-Orhan; J David McDonald
Journal:  Free Radic Biol Med       Date:  2002-05-01       Impact factor: 7.376

7.  The behavioral profile of severe mental retardation in a genetic mouse model of phenylketonuria.

Authors:  Simona Cabib; Tiziana Pascucci; Rossella Ventura; Valentino Romano; Stefano Puglisi-Allegra
Journal:  Behav Genet       Date:  2003-05       Impact factor: 2.805

8.  Relationship between myelin production and dopamine synthesis in the PKU mouse brain.

Authors:  Bernadin Joseph; Charissa A Dyer
Journal:  J Neurochem       Date:  2003-08       Impact factor: 5.372

9.  Lipophilic antioxidants in patients with phenylketonuria.

Authors:  Catrina Colomé; Rafael Artuch; Maria-Antònia Vilaseca; Cristina Sierra; Núria Brandi; Nilo Lambruschini; Francisco J Cambra; Jaume Campistol
Journal:  Am J Clin Nutr       Date:  2003-01       Impact factor: 7.045

Review 10.  Microglia as neuroprotective, immunocompetent cells of the CNS.

Authors:  Wolfgang J Streit
Journal:  Glia       Date:  2002-11       Impact factor: 8.073

View more
  4 in total

1.  PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah(enu2) mice.

Authors:  Jennifer E Embury; Catherine E Charron; Anatoly Martynyuk; Andreas G Zori; Bin Liu; Syed F Ali; Neil E Rowland; Philip J Laipis
Journal:  Brain Res       Date:  2006-11-15       Impact factor: 3.252

2.  MTF-1-mediated repression of the zinc transporter Zip10 is alleviated by zinc restriction.

Authors:  Louis A Lichten; Moon-Suhn Ryu; Liang Guo; Jennifer Embury; Robert J Cousins
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

3.  5-Hydroxytryptophan during critical postnatal period improves cognitive performances and promotes dendritic spine maturation in genetic mouse model of phenylketonuria.

Authors:  Diego Andolina; David Conversi; Simona Cabib; Antonio Trabalza; Rossella Ventura; Stefano Puglisi-Allegra; Tiziana Pascucci
Journal:  Int J Neuropsychopharmacol       Date:  2010-11-01       Impact factor: 5.176

4.  Early-onset behavioral and neurochemical deficits in the genetic mouse model of phenylketonuria.

Authors:  Elena Fiori; Diego Oddi; Rossella Ventura; Marco Colamartino; Alessandro Valzania; Francesca Romana D'Amato; Vibeke Bruinenberg; Eddy van der Zee; Stefano Puglisi-Allegra; Tiziana Pascucci
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.